Ascentawits - Crunchbase Company Profile & Funding

Q: Where is Ascentawits's headquarters?

Ascentawits is located in Shenzhen, Guangdong, China.

Q: Who invested in Ascentawits?

Ascentawits has 7 investors including Sangel Capital And CICC.

Q: When was the last funding round for Ascentawits?

Ascentawits closed its last funding round on obfuscated from a Series A round.

Q: How much funding has Ascentawits raised to date?

Ascentawits has raised obfuscated.

Overview

Ascentawits

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

+2 more milestones

See more interactive data and historical milestones on desktop for the best experience

About Ascentawits

CB Rank

56607

Ascentawits focuses on developing small molecule targeted conjugated anti-tumor drugs.

Founded

obfuscation

Private

Series A

Shenzhen, Guangdong, China

51-100

www.ascentawits.com

Biotechnology

Medical

Pharmaceutical

Product Research

Funding Rounds

Series A

OBF

obfuscation

Series A

OBF

obfuscation

Details

Legal Name

Shenzhen Aixindawei Pharmaceutical Technology Co., Ltd.

Also Known As

深圳艾欣达伟医药科技有限公司, Aixindawei

Operating Status

Active

Company Type

For Profit

About the Company

Ascentawits focuses on developing small molecule targeted conjugated anti-tumor drugs. The company utilizes specific tumor micro-environments to carry out independent innovative drug designs and screening for the development of new anti-tumor drugs.

Phone Number

0755-27888161

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

AST-3424

A small molecule targeted chemotherapy drug for malignant tumors, designed to selectively kill tumor cells expressing AKR1C3 enzyme.

AST-006 (TH-302)

A small molecule hypoxia-activated prodrug targeting PARP inhibitor-resistant cancers by inducing DNA double-strand breaks in hypoxic tumor environments.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Ascentawits	3	obfuscated obfuscation	—	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Sangel Capital	—	Series A - Ascentawits	—
Sangel Capital	—	Series A - Ascentawits	—
Sangel Capital	—	Series A - Ascentawits	—
Sangel Capital	—	Series A - Ascentawits	—
Sangel Capital	—	Series A - Ascentawits	—